Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Income from Continuing Operations (2016 - 2025)

Karyopharm Therapeutics' Income from Continuing Operations history spans 14 years, with the latest figure at 90185000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 392.24% year-over-year to 90185000.0; the TTM value through Dec 2025 reached 3656000.0, up 95.22%, while the annual FY2025 figure was 3656000.0, 95.22% up from the prior year.
  • Income from Continuing Operations reached 90185000.0 in Q4 2025 per KPTI's latest filing, up from 33127000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 101186000.0 in Q4 2023 to a low of 57414000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 16981200.0, with a median of 34316000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 1185.43% in 2021, then crashed 256.57% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 68740000.0 in 2021, then tumbled by 156.06% to 38537000.0 in 2022, then skyrocketed by 362.57% to 101186000.0 in 2023, then tumbled by 130.5% to 30860000.0 in 2024, then skyrocketed by 392.24% to 90185000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Income from Continuing Operations are 90185000.0 (Q4 2025), 33127000.0 (Q3 2025), and 37252000.0 (Q2 2025).